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ecause JunB is an essential gene for placentation, it
was conditionally deleted in the embryo proper.
 
JunB
 
 
 
/
 
 
 
 mice are born viable, but develop severe low
turnover osteopenia caused by apparent cell-autonomous
osteoblast and osteoclast defects before a chronic myeloid
leukemia-like disease. Although JunB was reported to be a
negative regulator of cell proliferation, 
 
junB
 
 
 
/
 
 
 
 osteoclast
precursors and osteoblasts show reduced proliferation
 
along with a differentiation defect in vivo and in vitro
 
.
 
Mutant osteoblasts express elevated p16
 
INK4a
 
 levels, but
exhibit decreased cyclin D1 and cyclin A expression. Runx2
B
 
is transiently increased during osteoblast differentiation in
 
vitro, whereas mature osteoblast markers such as osteocalcin
and bone sialoprotein are strongly reduced. To support a
 
cell-autonomous function of JunB in osteoclasts, 
 
junB
 
was inactivated speciﬁcally in the macrophage–osteoclast
lineage. Mutant mice develop an osteopetrosis-like pheno-
type with increased bone mass and reduced numbers of
osteoclasts. Thus, these data reveal a novel function of JunB
as a positive regulator controlling primarily osteoblast as
well as osteoclast activity.
 
Introduction
 
Bone is subject to constant remodelling as a result of the
complementary activities of two main cell types. Osteoblasts
(the bone-forming cells) originate from mesenchymal pro-
genitors and osteoclasts (the bone-resorbing cells) derive from
hematopoietic precursors within the monocyte–macrophage
lineage (Karsenty and Wagner, 2002). Both of these cell
types interact at the progenitor level through signals that
influence activation and differentiation. Osteoblast progenitors
or bone marrow stromal cells are stimulated by agents such
as 1,25-dihydroxyvitamin D
 
3
 
 or parathyroid hormone. After
stimulation, osteoblasts synthesize macrophage colony–
stimulating factor (M-CSF) and the tumor necrosis factor-
related cytokine receptor activator of NF
 
 
 
B ligand (RANKL),
two cytokines essential for osteoclastogenesis (Karsenty and
Wagner, 2002). During osteoblast and osteoclast prolifera-
tion and differentiation, precursor cells express different
stage-specific markers. The transcriptional mechanisms
responsible for the expression of stage-specific genes are still
not fully understood. However, some osteoclast-specific
genes such as tartrate-resistant acid phosphatase (TRAP),
carbonic anhydrase II, or matrix metalloproteinase-9 (MMP-9)
and osteoblast marker genes such as osteocalcin or bone si-
aloprotein have been shown to be target genes of the tran-
scription factor activator protein-1 (AP-1; Yamauchi et al.,
1996; Aslam et al., 1999; David et al., 2001; Simon et al.,
2001). The transcription factor NFATc1 has recently been
identified as a key regulatory protein, which together with
the AP-1 protein c-Fos, controls the terminal differentiation
of osteoclasts downstream of RANKL signaling (Takayanagi
et al., 2002).
AP-1 is a dimeric transcription factor composed of members
of the Jun family (c-Jun, JunB, and JunD), which form
homodimers or heterodimers with members of the Fos family
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(c-Fos, Fra-1, Fra-2, and FosB) and ATF proteins (ATF-2,
ATF-3, ATFa, and ATF-4; Shaulian and Karin, 2002). AP-1
modulates the transcription of target genes by binding to their
TRE or CRE consensus element (Shaulian and Karin, 2002).
Although AP-1 is involved in different biological processes
such as proliferation, differentiation, apoptosis, and transfor-
mation, specific roles for AP-1 in skeletal development have
been uncovered mainly through genetic studies in mice (Jo-
chum et al., 2001; Eferl and Wagner, 2003). The absence of
c-Fos leads to a complete block in osteoclast differentiation
and to the development of osteopetrosis (Grigoriadis et al.,
1994). Conversely, transgenic mice overexpressing c-Fos de-
velop osteosarcomas due to osteoblast transformation (Grigo-
riadis et al., 1993). Transgenic mice overexpressing Fra-1 or
 
 
 
FosB, a splice variant of FosB, develop osteosclerosis caused
by accelerated differentiation of osteoprogenitors into mature
osteoblasts (Jochum et al., 2000; Sabatakos et al., 2000).
Moreover, the loss of Fra-1 results in an osteopenic phenotype
due to reduced bone formation (unpublished data).
In contrast to Fos proteins, little is known about the role
of Jun proteins in bone development. Inactivation of c-Jun
and JunB in mice results in embryonic lethality (Eferl et al.,
1999; Schorpp-Kistner et al., 1999), whereas mice lacking
JunD are viable (Thepot et al., 2000). Overexpression of
c-Jun (Grigoriadis et al., 1993), JunB (Schorpp et al., 1996),
or JunD (unpublished data) did not result in an overt bone
phenotype. However, chondrocyte-specific inactivation of
c-Jun results in severe scoliosis caused by failure of interver-
tebral disc formation, suggesting that c-Jun is a regulator of
sklerotomal differentiation (Behrens et al., 2003). In addi-
tion, c-Jun was found to be essential for efficient osteoclasto-
genesis in vitro (David et al., 2002). The embryonic lethality
caused by lack of JunB and characterized by placental defects
can be rescued by inter-crossing 
 
junB
 
 
 
/
 
 
 
 with Ubi-
 
junB
 
transgenic mice. However, these mice develop a chronic my-
eloid leukemia (CML)-like disease due to loss of expression
of the 
 
junB
 
 transgene in the myeloid lineage (Passegue et al.,
2001), implying that JunB is a negative regulator of myeloid
progenitors and can act as a tumor suppressor gene.
Here, we report that the embryonic lethality in the absence
of JunB can also be rescued using a conditional gene-targeting
approach. Mice with a floxed 
 
junB
 
 allele were generated and
crossed to mice carrying the Mox2-Cre (MORE-
 
cre
 
) knock-in
allele, which restricts Cre recombinase activity to the embryo
(Tallquist and Soriano, 2000). Mutant mice with conditional
deletion of 
 
junB
 
 in the embryo—
 
junB
 
 
 
/
 
 
 
 mice—are viable
and born with Mendelian ratios. However, loss of JunB results
in reduced bone formation and severe low turnover osteope-
nia besides the CML-like disease. The osteopenia is mainly
due to a cell-autonomous osteoblast and osteoclast prolifera-
tion and differentiation defect, revealing a novel role for JunB
as a positive regulator of cell proliferation in bone cells.
 
Results
 
Conditional rescue of the embryonic lethality
 
To investigate the role of JunB in advanced embryonic devel-
opment and adulthood, a floxed allele of 
 
junB (junB
 
f
 
/
 
f
 
) was in-
troduced into embryonic stem (ES) cells by homologous re-
combination (Fig. 1 A). The neomycin resistance and the
 
thymidine kinase genes were removed by flp-mediated recom-
bination, and correct targeting was confirmed by Southern
blot analysis. Homozygous 
 
junB
 
f
 
/
 
f
 
 mice are viable and indistin-
guishable from wild-type mice, indicating that the floxed 
 
junB
 
alleles are not causing an overt phenotype. To rescue the em-
bryonic lethality likely caused by placental defects, 
 
junB
 
f
 
/
 
f
 
 mice
were crossed to MORE-Cre mice, where Cre recombinase is
expressed from the epiblast-specific 
 
Mox2
 
 locus, thus restricted
to the embryo proper (Tallquist and Soriano, 2000). MORE-
Cre 
 
junB
 
f
 
/
 
f
 
 (
 
junB
 
 
 
/
 
 
 
) mice are born with Mendelian frequen-
cies. However, already at the age of 4 wk, mutant mice devel-
oped a severe osteopenia that progressed with increasing age
(Fig. 1 B; Fig. 2, A and C). After 3–6 mo, mutant mice ac-
quired a myeloproliferative CML-like disease with massive in-
filtration of neutrophilic granulocytes in bone marrow and
spleen (Fig. 1 C), as has previously been described for mice
lacking JunB in the myeloid compartment (Passegue et al.,
2001). The efficiency of the 
 
junB
 
 deletion was confirmed in
different tissues and in isolated bone cells of adult 
 
junB
 
 
 
/
 
 
 
 mice
by Southern blot analysis (Fig. 1 D). Moreover, the absence of
 
junB
 
 expression was also verified by Northern blot using RNA
from different tissues (Fig. 1 E) and by Western Blot for JunB
protein from isolated osteoblasts and osteoclasts (Fig. 1 F).
 
Severe osteopenia in 
 
junB
 
 
 
/
 
 
 
 mice
 
No obvious bone phenotype was observed in 
 
junB
 
 
 
/
 
 
 
 new-
borns, whereas the number of osteoblasts was already re-
duced at 7 d of age (unpublished data). At 4 wk of age, the
mice had thinner and brittle bones. At 6 mo of age, tibia
bone length was reduced in 
 
junB
 
 
 
/
 
 
 
 mice compared with
controls (21 
 
 
 
 1 mm in 
 
junB
 
f/
 
 
 
 and 16 
 
 
 
 1 mm in 
 
junB
 
 
 
/
 
 
 
mice). Detailed histological analysis of vertebrae revealed de-
creased bone mass at the age of 1 mo, which progressed rap-
idly until the age of 6 mo (Fig. 2 A). Cortical bone thickness,
the most important parameter for biomechanical strength,
was analyzed using micro-CT. Femoral cortical thickness
was reduced from 350 
 
 
 
m in 
 
junB
 
f/
 
 
 
 controls to 142 
 
 
 
m in
 
junB
 
 
 
/
 
 
 
 mice at 6 mo of age (Fig. 2 B). Biomechanical mea-
surements (force to failure) using three-point bending re-
vealed that femoral diaphyseal bone strength of 
 
junB
 
 
 
/
 
 
 
 ani-
mals was significantly decreased (Fig. 2 F). When force to
failure is corrected for geometry, the breaking strength of the
bones in JunB
 
f/
 
 
 
 is 114.63 MPa and in JunB
 
 
 
/
 
 
 
 79.05 MPa,
demonstrating that the intrinsic property as well as the
breaking load of the bones is JunB dependent.
Static histomorphometric analysis on lumbar vertebral bod-
ies of 
 
junB
 
 
 
/
 
 
 
 and control mice at three different time points
(1, 3, and 6 mo) revealed that bone volume and trabecular
thickness are up to 30–40% decreased in 
 
junB
 
 
 
/
 
 
 
 mice (Fig. 2,
C and D). However, the number and separation, i.e., the dis-
tance between trabeculae, were not significantly changed (Fig.
2 E; unpublished data). These results are characteristic for low
turnover osteopenia, which results from a defect in osteoblast
function. The number of osteoblasts was reduced by up to
90% (Fig. 2 G), and osteoclast numbers were also reduced by
70% (Fig. 2 H). Similar results were obtained for tibial meta-
physes (unpublished data). Consistent with lower osteoclast
numbers, bone resorption in vivo was also significantly re-
duced in 1- and 3-mo-old mice, as assessed by measuring
urine deoxypyridinoline cross-links (Fig. 2 I). 
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Dynamic histomorphometric analysis showed that corti-
cal bone formation rate was reduced to 60% after 1 mo
and to 40% after 3 mo (Fig. 2 J), whereas trabecular bone
formation rate was reduced to 70% after 1 mo and to 30%
after 3 mo (Fig. 2 K). Osteocyte numbers and morphology
within the tibial cortex were not changed, and polarized
microscopy demonstrated that the cortex in 
 
junB
 
 
 
/
 
 
 
 mice
consisted of normal lamellar bone, as seen in controls (un-
published data). The structure of the epiphyseal growth
plate and the cartilage seemed normal (unpublished data).
Because loss of JunB in the myeloid compartment in Ubi-
 
junB
 
/
 
junB
 
 
 
/
 
 
 
 mice has previously been shown to cause a
CML-like disease (Passegue et al., 2001), we wanted to ex-
clude that the development of CML is responsible for the
 
bone phenotype in 
 
junB
 
 
 
/
 
 
 
 mice. Histomorphometry of 11-
mo-old Ubi-
 
junB
 
/
 
junB
 
 
 
/
 
 
 
 mice, where JunB expression is
lost in the granulocyte compartment, was performed. No
decrease in bone volume, bone formation rate, and cellular
parameters could be detected in leukemic Ubi-
 
junB
 
/
 
junB
 
 
 
/
 
 
 
mice compared with controls (unpublished data), proving
that the described bone phenotype is independent of the
CML-like disease.
 
Osteoblast defects in the absence of JunB
 
To investigate the cellular defects leading to osteopenia in
 
junB
 
 
 
/
 
 
 
 mice, osteoblast markers were first analyzed in vivo by
in situ hybridization and real-time PCR of total femoral bone
RNA of 6-mo-old 
 
junB
 
 
 
/
 
 
 
 and control mice. The numbers of
Figure 1. Generation of mice harboring 
a floxed junB allele. (A) Schematic rep-
resentation of the targeting strategy used 
to generate a floxed allele of junB. The 
junB ORF is represented by a rectangle. 
The thymidine kinase-neomycin resistance 
gene (tkneoR) and the diphtheria toxin   
(DT ) gene are indicated; loxP sites are 
shown as triangles. Bg, BglII; Xb, XbaI; 
X, XhoI; P, PstI; H, HindIII; S, SmaI; A, 
AccI; As, Asp780; B, BalI, E, EcoRI. A 3  
HindIII/EcoRI probe (probe A) was used 
for Southern analysis of BalI-digested 
genomic DNA to identify the targeted 
allele in the ES cells. To detect the deletion 
of the floxed allele, a 5  PstI/HindIII probe 
(probe B) was used to analyze PstI-
digested genomic DNA for Southern blot. 
JunB transcripts on Northern blots were 
detected using an EcoRI probe of junB. 
(B) Histological analysis of the metaphy-
seal regions (distal femur) of junB
f/  
control and junB
 /  mice at 3 mo of age 
(Giemsa). Bar, 250  m. (C) A 6-mo-old 
junB
 /  mouse and a junB
f/  control litter-
mate are shown. Arrow indicates areas 
of CML-associated infiltrates. Histological 
sections (HE) of normal bone marrow in 
junB
f/  control (top right) and myelopro-
liferative infiltrates in junB
 /  mice (bottom 
right). Bar, 20  m. (D) Southern blot 
showing deletion of junB in osteoblasts, 
osteoclasts, long bone, bone marrow, 
and liver. (E) mRNA expression of junB 
in different tissues of 3-mo-old junB
 /  
mice and wild-type controls;  -actin 
serving as loading control. (F) Western 
blot showing protein expression levels of 
JunB in osteoblasts after 2, 4, and 6 d of 
proliferation, and in osteoclasts, both 
cultured in proliferative conditions.616 The Journal of Cell Biology | Volume 164, Number 4, 2004
junB
 /  cells expressing osteopontin, an early osteoblast and late
hypertrophic chondrocyte marker, were unchanged compared
with controls. In contrast, both the numbers of cells expressing
collagen type 1a2 and osteocalcin, a late marker of osteoblast
function, and the signal intensity per cell were severely re-
duced, supporting an osteoblast defect in vivo (Fig. 3 A). In to-
tal bone extracts, mRNA levels of runx2 were significantly in-
creased, whereas mRNA levels of alkaline phosphatase ( alp),
bone sialoprotein ( bsp),  osteocalcin ( oc),  collagen type 1a2
(col1a2), rankl, and osteoprotegerin were significantly reduced,
Figure 2. Analysis of the bone phenotype of junB
 /  mice. (A) Histological analysis of vertebrae of junB
f/  control littermate and junB
 /  mice 
at 1, 3, and 6 mo of age. Trabecular and cortical bone is stained black (von Kossa staining). (B) micro-CT of vertebral bodies of 3-mo-old junB
f/  
control littermate and junB
 /  mice. The surfaces of trabecular and cortical bone are shown in red. Cortical micro-CT of 3- and 6-mo-old femora 
from junB
f/  and junB
 /  control mice. Histomorphometrical analysis of structural bone parameters in 1-, 3-, and 6-mo-old mice (C–E), and of 
cellular and dynamic parameters in 1- and 3-mo-old mice (G–K). (C) Trabecular bone volume (BV/TV; %). (D) Trabecular thickness (Tb/Th; mm). 
(E) Trabecular number (TbN; /mm). (F) Femoral whole-bone mechanical properties were determined by measuring fracture energy (force to 
failure; N). (G) Number of osteoblasts/bone perimeter (NOb/BPm; /mm). (H) Number of osteoclasts/bone perimeter (NOc/BPm; /mm). (I) Urine 
deoxypyridinoline cross-links (nM/mM creatinine) in 1- and 3-mo-old mice. (J) Cortical bone formation rate (mm
3/mm
2/year). (K) Trabecular 
bone formation rate (mm
3/mm
2/year). Bars represent mean values   SD. Results from five mice of each genotype are shown.Bone defects in the absence of JunB | Kenner et al. 617
in agreement with lower absolute numbers of osteoblasts in
vivo (Fig. 2 G). Expression levels of osteopontin (opn) were un-
changed (Fig. 3 B). Because RANKL synthesis by osteoblasts is
essential for efficient osteoclastogenesis, the decreased synthesis
due to reduced osteoblast numbers could also contribute to re-
duced osteoclast numbers in vivo, in addition to a cell-autono-
mous osteoclast differentiation defect (see Fig. 5). Moreover, in
vivo analysis of osteoblast proliferation revealed a 50% reduction
of Ki-67–positive osteoblasts in long bones (junB
f/  55.6  
3.1%; junB
 /  29.7   1.1% Ki-67–positive osteoblasts).
Next, proliferation and differentiation of primary calvarial
osteoblasts were analyzed in vitro. The proliferation rate of
junB
 /  calvarial osteoblasts, determined by BrdU incorpo-
ration, was reduced by 50% after a 2-d culture period (Fig. 4
A). To study the molecular mechanism responsible for the
osteoblast proliferation defect, flow cytometry and Western
Blot analyses of cell cycle regulators were performed. Serum-
starved and restimulated junB
 /  osteoblasts showed reduced
BrdU incorporation by FACS
® analysis and delayed S-phase
entry (Fig. 4 B). Mutant osteoblasts expressed both reduced
amounts of cyclin D1 and cyclin A protein, whereas the
expression of cyclin E and p21 were not changed (Fig. 4
C, and unpublished data). Interestingly, the expression of
p16
INK4a was up-regulated in junB
 /  osteoblasts (Fig. 4 C),
contrasting previous results in fibroblasts and granulocytes
(Passegue and Wagner, 2000; Passegue et al., 2001). Levels
of c-Jun were increased at all time points (Fig. 4 C) confirm-
ing analysis from other cell types (Chiu et al., 1989).
The differentiation potential of mutant osteoblasts was ana-
lyzed in vitro by staining high density cultures after 3 wk for
the deposition of mineralized ECM (bone nodules) and for al-
kaline phosphatase activity. In mutant cultures, bone nodule
formation was severely reduced and alkaline phosphatase–pos-
itive cells were almost absent (Fig. 4 D). To study candidate
molecules responsible for the observed cellular defects, the ex-
pression of marker genes was analyzed by real-time PCR in
cultures at d 1, 5, 8, 12, and 16 during in vitro differentiation.
Interestingly, expression levels of transcripts for runx2 and
rankl were transiently up-regulated at d 5 and 8 in junB
 / 
cells, whereas mRNA expression of collagen type 1a2 (col1a2),
alkaline phosphatase (alp), bone sialoprotein (bsp), and osteocal-
cin (oc) were strongly reduced at all time points in mutant os-
teoblasts (Fig. 4 E). mRNA expression of osteopontin and os-
teonectin were not changed (unpublished data). To determine
whether the defect in osteoblast differentiation is not due to
the reduced proliferative potential, we counted cell numbers
after plating cells at high density normally used for differentia-
tion experiments (5   10
5 cells/6-well). After 6 d in culture,
control osteoblasts reached a density of 1.4   10
6 cells/well,
whereas junB
 /  osteoblasts had a slightly reduced cell density
of 1.2   10
6 cells/well. Thus, mutant osteoblasts are capable
of acquiring a multilayer structure necessary for differentia-
tion, yet late osteoblast markers are down-regulated.
JunB affects osteoclast differentiation and proliferation
To study the role of JunB in osteoclast differentiation, bone
marrow precursor cells were cultured for 6 d in the presence
of M-CSF and RANKL (Fig. 5, A–C). When cultured on
plastic, differentiation of junB
 /  precursors into multinucle-
ated, TRAP-positive osteoclasts was drastically reduced to
10% compared with control cultures (Fig. 5 B). This differ-
entiation defect could not be fully rescued by culture on bo-
vine bone slices (Fig. 5 C) or by reciprocal coculture experi-
ments on junB
 /  or wild-type osteoblast feeder layers (Fig. 5
D). However, mutant and wild-type osteoblasts had the
same potential to support osteoclastogenesis of control bone
marrow, indicating a cell-autonomous osteoclast differentia-
tion defect in junB
 /  mice. Osteoclast resorptive activity
was evaluated by reflective light microscopy and was ad-
justed for the number of osteoclasts. There was no difference
in relative resorptive activity, indicating that mutant osteo-
clasts are functional (Fig. 5 E).
Figure 3. Analysis of osteoblast marker gene expression in vivo. (A) Analysis of osteocalcin (oc), collagen type 1a2 (col1a2), and osteopontin 
(opn) by in situ hybridization. Shown are the distal metaphysis in 2-mo-old mice; osteoblasts indicated by arrows. Bar, 50  m. (B) Real-time 
PCR of runx2, osteopontin (opn), alkaline phosphatase (alp), bone sialoprotein (bsp), osteocalcin (oc), collagen1a2 (col1a2), osteoprotegerin 
(opg), and rankl from total femoral bone mRNA of 6-mo-old mice. Expression levels were normalized to tubulin expression. Values are presented 
as relative expression. Bars represent mean values   SD (n   3).618 The Journal of Cell Biology | Volume 164, Number 4, 2004
Proliferation of osteoclast precursors was measured by
BrdU incorporation of preosteoclasts cultured on plastic
only in the presence of M-CSF. A 50% reduction in in-
corporation was observed in mutant cultures after a 2-d
culture period (Fig. 5 F), whereas no apparent difference
in TUNEL-positive osteoclasts was detected (unpublished
data). These data demonstrate that JunB is necessary for
both proliferation of osteoclast progenitors as well as for os-
teoclast differentiation in vitro.
To study gene expression in the osteoclast lineage, real-time
PCR was performed on primary differentiated osteoclasts and
from total bone RNA. The expression of mature osteoclast
markers and known AP-1 target genes such as TRAP, carbonic
anhydrase II, and MMP-9 was significantly reduced in mutant
osteoclasts in vitro (unpublished data) and in vivo (Fig. 5 G).
Comparable levels were found for cathepsin K and Mi-
crophthalmia-associated transcription factor (Fig. 5 G; unpub-
lished data), indicating that not all mature osteoclast markers
Figure 4. Analysis of osteoblast prolif-
eration and differentiation in vitro. (A) 
BrdU incorporation into junB
f/  control 
and junB
 /  osteoblast cultures and num-
bers of BrdU-positive osteoblasts. Bars 
represent mean values   SD (n   3). (B) 
FACS
® analysis of BrdU incorporation in 
serum-starved and restimulated control 
and junB
 /  osteoblasts. (C) Cell cycle 
profile in synchronized serum-induced 
osteoblasts of cyclin A, cyclin D1, p16, 
p21, c-Jun, and actin using Western blot 
analysis. (D) Formation of mineralized 
ECM by neonatal calvarial osteoblast 
cultures from junB
f/  and junB
 /  control 
littermates. Mineralized nodules are 
stained by Alizarin S red (top). Osteoblast 
cultures were also stained for alkaline 
phosphatase activity (ALP, bottom). (E) 
Real-time PCR of runx2, collagen type 
1a2 (col1a2), alkaline phosphatase (alp), 
bone sialoprotein (bsp), osteocalcin (oc), 
and rankl from junB
f/  control and junB
 /  
osteoblasts at 1, 5, 8, 12, and 16 d of 
differentiation. Expression levels were 
normalized to tubulin expression and 
were presented as relative expression. 
One representative result of three inde-
pendent osteoblast cultures is shown.Bone defects in the absence of JunB | Kenner et al. 619
are down-regulated in the absence of JunB. Moreover, no
changes in expression levels for RANK, M-CSF receptor, GM-
CSF receptor  , and G-CSF receptor were found (unpublished
data), suggesting that cytokine responsiveness of mutant os-
teoclast precursors is apparently not altered.
A cell-autonomous role of JunB in the osteoclast lineage
To test whether the osteoclast differentiation defect is intrin-
sic to the osteoclast lineage, junB
f/f mice were crossed to
Lysozyme-M-cre mice (Clausen et al., 1999), deleting junB in
the macrophage–osteoclast lineage (junB
 / m /OC). Mice are born
viable and without obvious signs of disease. Southern blot anal-
ysis showed complete deletion of junB in junB
 / m /OC osteo-
clasts, whereas junB was only partially deleted in sorted granu-
locytes (unpublished data). Histological and radiographical
analysis of long bones from 3-mo-old mutant mice showed in-
creased trabecular bone volume and increased radiodensity, re-
spectively (Fig. 6 A). In 11-mo-old mice, analysis of junB
 / m /OC
humeri revealed a profound increase in both numbers and
diameter of trabeculae. The patterning of trabecular bone
seemed to be irregular and occupied the whole diaphysis shaft
(Fig. 6 B). Osteoclasts appeared frequently mononuclear and
smaller than controls, indicating an osteoclast differentiation
defect (Fig. 6 C). The number of TRAP-positive osteoclasts in
vivo was greatly reduced, and histomorphometric analysis re-
vealed a 50% reduction in osteoclast numbers (Fig. 6 D).
Differentiation of junB
 / m /OC bone marrow precursors
into osteoclasts in vitro was significantly reduced to 16% of
control osteoclasts on both plastic (unpublished data) and
bone surfaces (Fig. 6 E). Moreover, proliferation of mutant
osteoclast precursors, as measured by BrdU incorporation of
M-CSF–treated preosteoclasts, was slightly, but not signifi-
cantly, reduced. These data indicate that loss of junB in os-
teoclast precursors results mainly in a cell-autonomous re-
duction of osteoclast differentiation in vivo and in vitro.
Discussion
Because JunB is essential for mouse development, a condi-
tional gene-targeting approach was used to study its function
Figure 5. Analysis of junB
 /  osteoclast prolifera-
tion and differentiation in vitro. (A) TRAP staining 
of osteoclasts cultured for 7 d on bovine bone discs 
induced by M-CSF and RANKL. (B) Numbers of 
differentiated osteoclasts grown on plastic for 7 d 
(n   4). (C) Numbers of differentiated osteoclasts 
grown on bone for 7 d (n   4). (D) Reciprocal 
cocultures of primary osteoblasts and bone marrow 
of the indicated genotypes under osteoclastogenic 
conditions followed by TRAP staining (n   4). (E) 
Relative resorptive activity of junB
f/  control and 
junB
 /  osteoclasts cultured on bovine bone for 7 d. 
Resorbed area was assessed by reflective light 
microscopy and corrected for the number of osteo-
clasts per disc. (F) BrdU incorporation into M-CSF–
treated osteoclast precursors and numbers of BrdU-
positive precursors after 2 d of culture (n   3). (G) 
Real-time PCR analysis of cathepsin K (cathK), TRAP, 
carbonic anhydrase II (caII), and MMP-9 in junB
f/  
and junB
 /  femoral bone mRNA of 6-mo-old mice. 
Expression levels were normalized to tubulin ex-
pression. Values are presented as relative expression. 
Bars represent mean values   SD (n   3).620 The Journal of Cell Biology | Volume 164, Number 4, 2004
postnatally. Embryonic lethality due to placental defects was
rescued by the expression of junB in the parietal endoderm
and trophectoderm lineage. This demonstrates that the de-
scribed trophoblast defect is the cause of lethality, further
supporting earlier findings with junB
 / ES cells and tetra-
ploid blastocyst injections (Schorpp-Kistner et al., 1999). The
rescued junB
 /  mice developed severe osteopenia as early as
1 mo after birth and exhibited decreased numbers of osteo-
blasts and osteoclasts in vivo. Bone formation, a function
specific to the osteoblast and quantified by dynamic histo-
morphometry, and bone resorption, a function specific to the
osteoclast and quantified by biochemical analysis of cross-
link excretion, were both decreased in junB
 /  mice com-
pared with controls. Because junB
 /  mice are osteopenic, the
reduction in bone formation exceeds the decrease in bone re-
sorption, which by itself would lead to more bone.
Reduced osteoclast differentiation in vivo might also be
partly due to reduced numbers of osteoblasts, and conse-
quently, reduced RANKL production in vivo. Moreover, the
defects in mice lacking junB were cell autonomous as revealed
by ex vivo cultures. Because the trabecular microarchitecture
remained unchanged, this phenotype resembles severe low
turnover osteopenia, similar to senile osteoporosis in aged hu-
mans. As previously described for mice lacking junB in the my-
eloid compartment (Passegue et al., 2001), mutant mice also
acquire a myeloproliferative CML-like disease after 3–6 mo.
A function of JunB as a transcriptional regulator important
for both osteoblast and osteoclast proliferation and differenti-
ation has not yet been documented in vivo using mice lacking
JunB. Previous in vitro experiments had suggested a role for
JunB in inducing the differentiation of mesenchymal progeni-
tors toward the osteoblastic phenotype, and junB mRNA
transcripts have been shown to be present during the prolifer-
ative period and during late stages of osteoblast development
(McCabe et al., 1995). In synchronized and proliferating os-
teoblasts lacking junB, we observed a delay in S-phase entry,
reduced levels of cyclin D1 and cyclin A protein, and in-
creased levels of the CDK inhibitor p16
INK4a, suggesting that
JunB positively regulates osteoblast proliferation. The finding
that p16 is induced in the absence of JunB is particularly sur-
prising because JunB has been found to be a negative regula-
tor of cell proliferation by activating p16. In fibroblasts, JunB
suppresses cell proliferation and induces premature senescence
by transcriptional activation of p16 (Passegue and Wagner,
2000). Moreover, absence of JunB leads to myeloid leukemia
with increased myeloid proliferation and decreased apoptosis
caused by down-regulation of p16 expression and up-regula-
tion of Bcl2 and of Bclx, clearly demonstrating that JunB can
act as a tumor suppressor gene in mice (Passegue et al., 2001).
Furthermore, reduced cyclin D1 protein levels in proliferat-
ing junB
 /  osteoblasts are also in contrast with previous analy-
ses in fibroblasts. JunB was able to negatively regulate the cy-
clin D1 promoter at the transcriptional level (Bakiri et al.,
2000), but also at the post-transcriptional level (Passegue et al.,
2002). In contrast to JunB, c-Jun can transcriptionally activate
cyclin D1 in fibroblasts (Wisdom et al., 1999). Consistent
with the notion that JunB acts as a transcriptional repressor of
c-Jun, junB
 /  osteoblasts displayed higher levels of c-Jun pro-
tein. However, the increased c-Jun protein did not result in in-
creased proliferation of osteoblasts. Decreased protein levels of
cyclin A in mutant osteoblasts may additionally contribute to
the reduced proliferation rate, confirming recent findings that
JunB can also have a cell cycle–promoting role by transcrip-
tionally activating the cyclin A promoter in fibroblasts (An-
drecht et al., 2002). Because there is no apparent change in ap-
optosis in junB
 /  osteoblasts, JunB does not appear to be
necessary for the regulation of survival in osteoblasts. These
data clearly indicate that JunB can act as a positive regulator of
cell proliferation. Similar alterations in cyclin A and p16 ex-
pression, associated with defects in osteoblast proliferation in
vitro, were observed in JunB-compromised cells isolated from
Ubi-junB/junB
 /  rescued mice (Hess et al., 2003).
Gene expression analyses of osteoblast-specific markers at
different time points during osteoblast differentiation in
Figure 6. Characterization of junB
 / m /OC Lysozyme-M-Cre mice. 
(A) Histological analysis of the metaphyseal regions (proximal tibia) 
of wild-type and junB
 / m /OC mice at 3 mo of age. Trabecular bone 
mass stained pink (HE staining). Bar, 500  m. X-ray analysis of long 
bones of junB
f/f control and junB
 / m /OC mice at 3 mo of age (insets). 
(B) Histological analysis of the metaphyseal regions (distal humerus) 
of wild-type and junB
 / m /OC mice at 11 mo of age. Bar, 500  m. 
(C) TRAP staining of the distal metaphysis humeri (bar, 50  m). 
Osteoclasts are stained red and indicated by arrows. Insets show 
osteoclasts at higher magnification (bar, 15  m). (D) Numbers of 
osteoclasts/bone perimeter (NOc/BPm) in metaphyseal regions of 
11-mo-old mice. (E) Numbers of differentiated TRAP-positive osteo-
clasts grown on bone (n   4). Bars represent mean values   SD.Bone defects in the absence of JunB | Kenner et al. 621
vitro showed that the mRNA expression levels of collagen
type 1a2, alkaline phosphatase, osteocalcin, and bone sialopro-
tein, which are restricted to more mature osteoblasts, were
strongly reduced in junB
 /  osteoblasts, whereas osteonectin
and osteopontin expression were not changed. Interestingly,
RANKL expression was increased in mutant osteoblasts at
early time points of culture, which might correlate with the
fact that JunB
 /  osteoblasts differentiate less and that im-
mature osteoblasts have higher levels of RANKL expression.
Although junB-deficient osteoblasts have a severe prolifer-
ation defect, cells plated at high density are still capable of
acquiring a multilayer structure. It cannot be excluded that
the severe differentiation defect observed in mutant osteo-
blasts is partly caused by the reduced proliferative potential.
However, both alkaline phosphatase and bone sialoprotein
have been shown to be expressed in proliferating, osteocal-
cin-negative osteoblastic cells, whereas osteocalcin expres-
sion is only initiated after cells exit from log-phase growth
(Malaval et al., 1999). Expression levels of all these genes are
dramatically reduced in junB-deficient osteoblast cultures,
suggesting a defect in osteoblast maturation in addition to
the severe effect on proliferation.
Surprisingly, a progressive decrease in osteocalcin levels after a
peak of expression at d 12 of culture was observed in wild-type
cultures. This contrasts with the common knowledge of osteo-
calcin being a late marker of mature osteoblasts, and might be
due to the heterogeneity of primary osteoblast cultures. Inter-
estingly, runx2 mRNA expression remains consistently up-reg-
ulated in the absence of JunB. Runx2 is an essential transcrip-
tion factor for osteoblast differentiation and bone formation
(Ducy et al., 1997; Komori et al., 1997). However, mice over-
expressing Runx2 from the collagen type I promoter develop
osteopenia due to an osteoblast maturation defect (Liu et al.,
2001). Overexpression of a dominant-negative Runx2 at a late
stage of osteoblast differentiation caused reduced expression of
bone matrix, again resulting in osteopenia (Ducy et al., 1999).
Therefore, Runx2 expression has to be tightly controlled, and
the increased expression of runx2 observed in junB
 /  osteo-
blasts might be responsible for the defect in osteoblast matura-
tion. This might indicate that JunB can function as a repressor
of Runx2 at specific stages of osteoblast differentiation. How-
ever, transcriptional targets of Runx2 such as collagen type I, os-
teocalcin, and alkaline phosphatase are down-regulated in junB
 / 
osteoblasts in vivo and in vitro. Thus, JunB might also be in-
volved in the induction of coactivators that are required for
Runx2-dependent transcriptional activation.
To investigate the role of JunB in osteoclast differentiation,
a number of putative AP-1 target genes as well as markers of
the osteoclast lineage were analyzed in vitro and in vivo. Inter-
estingly, junB
 /  osteoclasts had a proliferation and differenti-
ation defect, again contrasting the function of JunB as a nega-
tive regulator of cell proliferation. The loss of JunB expression
does not influence either the expression of Microphthalmia-
associated transcription factor or of cathepsin K. On the other
hand, TRAP, carbonic anhydrase II, and MMP-9 were down-
regulated, all known AP-1 target genes and important for os-
teoclast function and recruitment (Schorpp-Kistner et al.,
1999; David et al., 2001; Takayanagi et al., 2002).
To investigate whether the absence of JunB in the he-
matopoietic lineage would lead to a cell-autonomous bone
phenotype, JunB was inactivated selectively in the macro-
phage–osteoclast lineage (Clausen et al., 1999). Interestingly,
the mutant mice developed a severe osteopetrosis-like phe-
notype with markedly increased bone mass, strongly sup-
porting the hypothesis of a cell-autonomous osteoclast de-
fect. A similar but more severe osteopetrotic phenotype
caused by a complete block in osteoclast differentiation is
present in mice lacking c-Fos (Grigoriadis et al., 1994). In-
terestingly, this differentiation block could be rescued most
efficiently by Fra-1 in vitro, but not by any of the Jun pro-
teins (Matsuo et al., 2000). Therefore, it is possible that
JunB might be the partner of c-Fos in osteoclastogenesis.
Together, mice lacking JunB only in the macrophage–
osteoclast lineage are osteopetrotic and show increased bone
mass, whereas they are severely osteopenic with a dominant
osteoblast phenotype when JunB is missing in all bone cells.
This implies that JunB is a key regulator of skeletogenesis af-
fecting bone formation more strongly than bone resorption.
These data further question the concept that there is a tight
cross-talk between osteoblasts and osteoclasts during bone re-
modeling, which is in agreement with previous reports chal-
lenging this hypothesis (Corrall et al., 1998; Amling et al.,
2000). The novel function of JunB as a positive regulator of
bone remodelling opens new strategies to be used for prevent-
ing bone loss. Furthermore, JunB
 /  mice provide an excellent
model to study mechanisms leading to age-related bone loss.
Materials and methods
Generation of junB
f/f mice
A floxed and frt-flanked neomycin resistance and thymidine kinase gene
selection cassette was inserted into a SmaI site present in the 5  untrans-
lated region of junB. The 3  loxP site was inserted into the XhoI site, 161
bp downstream of the translation stop codon. A diphtheria toxin gene was
included for selection against random integrants. The linearized targeting
construct was electroporated into HM-1 ES cells, and the identification of
homologous recombinants by PCR using two sets of primers was per-
formed as described previously (Schorpp-Kistner et al., 1999). The neomy-
cin and thymidine kinase genes were deleted by transient transfection of a
vector expressing flp recombinase. Two ES cell clones carrying a floxed al-
lele of junB were injected into C57BL/6 blastocysts, and several chimeras
from one ES cell clone transmitted the mutant allele to their offspring.
Mice
Mice carrying the floxed junB allele (junB
f/f) were crossed to MORE-Cre
mice (Tallquist and Soriano, 2000) and to Lysozyme-M-Cre mice (Clausen
et al., 1999; provided by I. Förster, University of Cologne, Cologne, Ger-
many). The genetic background of this intercross was C57Bl/6   129. Mu-
tant mice were intercrossed at least five times before bone histomorphom-
etry to increase genetic homogeneity. Only female mice were used for
quantitative histomorphometric measurements. Ubi-junB/junB
 /  mice
have been described previously (Passegue et al., 2001).
Southern, Northern, and Western blot analysis
For Southern blots, 10  g genomic DNA was digested with PstI, yielding a
2.3-kb fragment for the floxed junB allele and a 0.7-kb fragment for the de-
leted junB allele. For detection of the bands, a 176-bp PstI/HindIII fragment
of junB was used as a probe. Northern blot analysis was performed accord-
ing to standard procedures using an EcoRI fragment of junB and a fragment
of  -actin for loading control. Western blot analysis was performed ac-
cording to standard procedures using anti-cyclin A, anti-p16, anti-p21,
anti-cyclin D1, anti-cyclin E, anti-c-Jun (all from Santa Cruz Biotechnol-
ogy, Inc.), anti-actin (Sigma-Aldrich), and anti-JunB (M. Yaniv, Institut Pas-
teur, Paris, France) antibodies.
In situ hybridization analysis
For nonradioactive in situ hybridization, bones from 3-mo-old mice were
fixed overnight with neutral buffered 4% PFA at 4 C, decalcified for 10 d in622 The Journal of Cell Biology | Volume 164, Number 4, 2004
0.5 M EDTA, and embedded in paraffin. For in situ hybridization analysis,
sections were deparaffinized and hybridization was performed according to
standard procedures (Murtaugh et al., 1999). Osteopontin, collagen type
1a2, and osteocalcin mRNA were detected with DIG-labeled antisense
probes (probes were provided by C. Hartmann, IMP, Vienna, Austria).
All sections from histological and in situ hybridization stainings were
examined using a microscope (Axioskop2 mot; Carl Zeiss MicroImaging,
Inc.) with Plan-Apochromat 20 /0.75 lenses, 40 /0.95 Korr lenses, and
Plan-Neofluar 63 /1.25 oil lenses. Images were captured using a digital
image capture camera (AxioCam Mr Color; Carl Zeiss MicroImaging, Inc.).
Image analysis was performed using tools provided in the AxioVision 3.1
software package (Carl Zeiss MicroImaging, Inc.). The images were further
processed using Adobe Photoshop
® 7.0.
X-ray analysis, histomorphometry, and histological analysis
Mice were killed at 1 and 7 d and at 4, 12, and 24 wk of age. After
whole-animal contact radiography (using an x-ray cabinet; Faxitron),
mice were killed by cervical dislocation and bones were fixed in 3.7%
PBS-buffered formaldehyde. After dehydration, the undecalcified tibiae
and lumbar spines were embedded in methylmethacrylate, and 5- m
sections were cut in sagittal plane on a rotation microtome (Cut 4060E;
MicroTech) as described previously (Amling et al., 1999). Sections were
stained with toluidine blue, and with modified von Kossa/van Gie-
son. Quantitative histomorphometry was performed on toluidine blue–
stained, undecalcified proximal tibia and lumbar vertebra sections. For
comparative histomorphometry, samples from five JunB
f/  and five JunB
 / 
mice at 1, 3, and 6 mo of age were used. Analysis of bone volume (per-
centage), trabecular thickness (micrometers), trabecular number (per
mm), trabecular separation (micrometers), osteoblast number per bone
perimeter (per mm), osteoclast number per bone perimeter (per mm),
cortical thickness (micrometers), and trabecular and cortical bone forma-
tion rate ( m
3/ m
2/year) was performed according to standardized proto-
cols of the American Society for Bone and Mineral Research (Parfitt et
al., 1987) using the Osteomeasure histomorphometry system (Osteome-
trix). Experiments were performed in a blinded fashion. For assessment of
dynamic histomorphometric indexes, mice were injected with calcein
according to a standard double-labeling protocol (Amling et al., 1999).
Fluorochrome measurements were made on two nonconsecutive 12- m-
thick sections per animal. Sections were mounted unstained in Fluoro-
mount (Electron Microscopy Sciences).
Immunohistochemical staining for Ki67 (1:1,000, NCL-Ki67p; Novacos-
tra) was performed on paraffin sections of formaldehyde-fixed, decalcified
long bones using the ABC staining kit (Vector Laboratories) according to
the manufacturer’s recommendations.
Biomechanical testing and microcomputed tomography 
analysis ( CT)
Both femurs were stored in 50% ethanol-saline, transferred to isotonic sa-
line, and stored at 4 C for 12 h before testing. A three-point bending was
performed as described previously (Amling et al., 1999), using a commer-
cial high precision instrument (Z2.5/TN 1S testing machine; Zwick GmbH
& Co.). In brief, the ends of the bone were supported on two fulcra sepa-
rated by 5 mm. With the posterior aspect of the femur resting on the fulcra,
a load was applied from above to the anterior midshaft midway between
the two fulcra, at a constant speed of 10 mm/min to failure. A chart re-
corder was used to generate a force-deformation curve. The stiffness was
assessed as the slope of the force-deformation curve through its linear re-
gion. Experiments were performed in a blind fashion.
For three-dimensional histomorphometry and visualization of the verte-
bral bone structure, lumbar vertebra L6 of 3-mo-old mice was scanned in a
microCT40 scanner (Scanco Medical) at a 6- m resolution. The raw data
were manually segmented and analyzed with  CT Evaluation Program
v4.4A (Scanco Medical). For visualization, the segmented data were im-
ported and displayed in  CT Ray v3.0 (Scanco Medical). For assessment
of the femoral cortical thickness, femora were dissected out of 3- and
6-mo-old mice, and 20 planes were scanned at the midshaft in a microCT40
scanner at a 6- m resolution. Cortical thickness was measured with the
Distance 3D tool of the  CT Evaluation Program v4.4A (Scanco Medical).
For all histomorphometrical analyses, the results from five mice of each ge-
notype are shown.
Biochemical assays
We collected urine samples from sex- and age-matched mice. The urinary
excretion of deoxypyridinoline cross-links was determined using the Py-
rilinks-D ELISA and was expressed relative to urinary creatinine concentra-
tion (Metra Biosystems, Inc.).
PCR and real-time PCR analysis
PCR for genotyping of junB-deficient mice was performed with primers
B1 5 -atcctgctgggagcggggaactgagggaag-3 , B2 5 -gggaactgagggaagccacgc-
cgagaaagc-3 , B6 5 -agagtcgtcgtgatagaaaggc-3 , and B10 5 -aaacata-
caaaatacgctgg-3 . Real-time PCR was performed with cDNA synthesized
from 2  g RNA with random primers using the ready-to-go™ cDNA kit
(Amersham Biosciences) according to the manufacturer’s protocols. RNA
was isolated using the TRIzol
® procedure (Sigma-Aldrich). For real-time
PCR, cDNA was diluted to a final concentration of 3 ng/ l. For PCR reac-
tions, light cycler Fast Start DNA Master SYBR
® Green (Roche) was used.
Three independent measurements per sample were performed. Primer
pairs for osteoblast and osteoclast genes were used as follows: tubulin (391
bp) up 5 -caacgtcaagacggccgtgtg-3 , down 5 -gacagaggcaaactgagcacc-3 ;
runx2 (419 bp) up 5 -aacccacggccctccctgaactct-3 , down 5 -actggcggggtg-
taggtaaaggtg-3 ; col1a2 (445 bp) up 5 -tcgggcctgctggtgttcgtg-3 , down 5 -
tgggcgcggctgtatgagttcttc-3 ; ALP (479 bp) up 5 -cacgcgatgcaacaccactcagg-
3 , down 5 -gcatgtccccgggctcaaaga-3 ; OC (240 bp) up 5 -accctggct-
gcgctctgtctct-3 , down 5 -gatgcgtttgtaggcggtcttca-3 ; BSP (432 bp) up 5 -
taccggccacgctactttctttat-3 , down 5 -gaccgccagctcgttttcatcc-3 ; osteonec-
tin (417 bp) up 5 -acaacccctgccagaaccatcatt-3 , down 5 -cctccaggcgcttct-
cattctca-3 ; osteopontin (425 bp) up 5 -ctccttgcgccacagaatg-3 , down 5 -
tgggcaacagggatgaca-3 ; MMP-9 (423 bp) up 5 -gccctacagcgccccctact-3 ,
down 5 -agacacgccccttgctgaaca-3 ; cathepsin K (408 bp) up 5 -agggc-
caactcaagaagaaaact-3 , down 5 -tgccatagcccaccaccaacact-3 ; TRAP (405
bp) up 5 -ggccggccactaccccatct-3 , down 5 -caccgtagcgacaagcaggactct-
3 ; carbonic anhydrase II (534 bp) up 5 -tgtcaacaacggccactcctt-3 , down
5 -tcagcatccccctcctcattg-3 ; RANKL (407 bp) up 5 -gcttcactgcccagtct-
catcgtt-3 , down 5 -gggccggtccgtgtactcatcct-3 ; OPG (519bp) up 5 -ggaac-
cccagagcgaaacacagt-3 , down 5 -cttcttcccaggcaggctctccat-3 .
The comparative CT method was used to calculate the expression levels
of RNA transcripts. The quantified individual RNA expression levels were
normalized for the respective tubulin expression levels. Because we mea-
sured the relative RNA expression levels, the wild-type expression level
was set as 1.
Osteoblast and osteoclast cultures
Primary osteoblasts were isolated from calvariae of neonatal (2–4-d-old)
mice as described previously (Jochum et al., 2000). Cells were replated for
differentiation at 5   10
5 cells/well, or for proliferation at 10
5 cells/well in
a 6-well plate. For differentiation, medium was supplemented with 5 mM
 -glycerophosphate and 100  g/ml ascorbic acid. After 3 wk of culture,
bone nodules were identified morphologically by Alizarin S red staining
(Sigma-Aldrich). Staining of cultures for alkaline phosphatase activity was
performed using a Sigma Kit 86R.
For differentiating and proliferating osteoclast cultures, primary bone
marrow cells from 6–10-wk-old mice were cultured as described previ-
ously (Fuller et al., 2000) in 20 ng/ml M-CSF and 5 ng/ml RANKL (R&D
Systems) for 6 d on plastic or for 7 d on cortical bovine bone slices (pro-
vided by O. Hoffmann, University of Vienna, Vienna, Austria), or in 20 ng/
ml M-CSF on plastic for proliferation analyses of preosteoclasts. To test re-
sorptive activity on bone slices, culture medium was acidified to pH  7.0
for the last 2 d of culture to activate resorption. Resorption pits were
stained with toluidine blue. Co-culture experiments with primary osteo-
blasts were performed as described previously (Jochum et al., 2000).
Microscopic analysis of osteoblast and osteoclast cultures was per-
formed using a stereomicroscope (MZ-Apo; Leica) with Plan-Apo 1.0 
lenses. The images were recorded using a CCD camera (DKC-5000; Sony)
using ImageAccess software (Imagic).
For BrdU incorporation, BrdU was added to the last 2 h (osteoblasts) or
6 h (M-CSF–treated osteoclast precursors) of proliferating cultures to a final
concentration of 10 mM. Cells were immunostained with anti-BrdU antibody
(Abcam) according to standard procedures. In situ nick end-labeling (TUNEL)
was performed using the in situ cell death detection kit II (Boehringer).
For analysis of synchronized osteoblasts, cells were cultured for 1 d and
thereafter serum-starved. After 48 h, MEM with 15% FCS was added and
osteoblasts were analyzed at 0-, 4-, and 8-h time points. For FACS
® analy-
sis for cell cycle profiling of proliferating osteoblasts, BrdU was added at
restimulation and osteoblasts were fixed in 85% ethanol. All cell culture
assays were performed at least two times (mostly three times), with four
replicates per experiment.
Statistics
Statistical analysis was performed using t test; P   0.05 was accepted as
significant. Error bars represent the SD.
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